Regeneron Still Has Legs: Leerink Targets $630 a Share
August 03, 2015 at 11:40 AM EDT
Leerink analysts Jason Schwartz and Mayank Mamtani have joined the other biotech industry pundits proclaiming that Regeneron Pharmaceuticals’ (REGN) run isn’t over. The pair raised their price target on the high-flying biotech stock to $630 from $559, partly to reflect last week’s FDA approval of the high cholesterol drug Praluent Schwartz and Mamtani see sales [...]